NCT04045496 - A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2019

Primary Completion Date

March 31, 2024

Study Completion Date

March 31, 2024

Conditions

Non-small Cell Lung CancerColorectal CancerPancreatic Ductal CarcinomaEsophageal Squamous Cell CarcinomaHead and Neck Squamous Cell CarcinomaBreast CancerOther Solid Tumors

Interventions

DRUG

JAB-3312

JAB-3312 will be supplied as 0.25 mg and 1.0 mg capsules.

Trial Locations (4)

37203

RECRUITING

Tennessee Oncology, PLLC, Nashville

63110

RECRUITING

Washington University School of Medicine, Seattle

77030

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

80202

RECRUITING

HealthONE Clinic Services Oncology-Hematology, Denver